Regeneron is a biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.
Marketed Products
Regeneron has received marketing approval from the U.S. Food and Drug Administration (FDA) for ARCALYST™ (rilonacept) Injection for Subcutaneous Use for a rare inflammatory condition.
Advanced Product Candidates
In clinical trials for a wide range of solid tumors.
In clinical trials for wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).
Regeneron also is evaluating the potential use of rilonacept in other indications in which IL-1 may play a role.
